NEW YORK, Aug 22 – Galapagos Genomics is collaborating with Vertex Pharmaceuticals to identify the function of various proteins, the company announced Wednesday.
Galapagos, a privately held company based in Mechelen, Belgium, will provide Vertex with recombinant adenoviruses via its PhenoSelect expression platform. Vertex plans to use the information for characterization of protein activity within targeted biological pathways.
Financial details of the collaboration were not disclosed.
In June, Galapagos announced a collaboration with Bayer Yakuhin , a subsidiary of German pharmaceutical giant Bayer, to provide recombinant adenoviruses containing asthma-associated human genes supplied by Bayer.